TY  - JOUR
AB  - Background & aims: Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease frequently coexist. While several blood-based indices exist for the detection of NAFLD, few studies have examined how alcohol use possibly impacts their diagnostic performance. We analysed the effects of alcohol use on the performance of indices for detecting fatty liver disease (FLD). Methods: We included participants from the Cardiovascular Risk in Young Finns Study (Finnish sample) and KORA study (German sample) who underwent abdominal ultrasound or magnetic resonance imaging, respectively, for detection of FLD and had serum analyses available for calculation of Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), Lipid Accumulation Product (LAP), and Dallas Steatosis Index (DSI). Alcohol use was estimated by questionnaires as mean daily consumption and binge drinking (Finnish sample only). Predictive performance for FLD was assessed according to alcohol consumption. Results: The study included 1426 (Finnish sample) and 385 (German sample) individuals, of which 234 (16%) and 168 (44%) had FLD by imaging. When alcohol consumption was <50 g/day, all indices discriminated FLD with area under the receiver operating characteristics (AUROC) of 0.82–0.88. AUROCs were 0.61–0.66 among heavy drinkers (>50 g/day). AUROCs decreased to 0.74–0.80 in the highest binge-drinking category (>2 times/week). Alcohol use correlated with FLI and LAP (r-range 0.09–0.16, p-range <.001–.02) in both samples and with DSI (r = 0.13, p < .001) in the Finnish sample. Conclusions: Indices perform well and comparably for detection of FLD with alcohol consumption <50 g/day and with different binge-drinking behaviour.
AU  - Danielsson, O.*
AU  - Nano, J.
AU  - Pahkala, K.*
AU  - Rospleszcz, S.
AU  - Lehtimäki, T.*
AU  - Schlett, C.L.*
AU  - Kähönen, M.*
AU  - Bamberg, F.*
AU  - Raitakari, O.*
AU  - Peters, A.
AU  - Nissinen, M.J.*
AU  - Åberg, F.O.*
C1  - 65508
C2  - 52201
SP  - 1349-1360
TI  - Validity of fatty liver disease indices in the presence of alcohol consumption.
JO  - Scand. J. Gastroenterol.
VL  - 57
IS  - 11
PY  - 2022
SN  - 0036-5521
ER  - 

TY  - JOUR
AB  - Impaired barrier function of the gut and inadequate immunological response to intestinal pathogens are the cornerstones in the pathogenesis of inflammatory bowel disease (IBD). CXCL16 is a protein which shares pattern recognition receptor functions, relevant for adhesion and phagocytosis of bacterial products, with the properties of an adhesion molecule and inflammatory chemokine. The relevance of CXCL16 in IBD has so far been elusive. This objective of this study was to determine the association between CXCL16 and IBD. Material and methods. Soluble CXCL16 (sol-CXCL16) serum levels in a cohort of 239 patients with Crohn's disease were measured, 114 patients with ulcerative colitis and 144 controls. Results. In a univariate analysis, sol-CXCL16 was found to be markedly increased in patients with Crohn's disease or ulcerative colitis compared with that in controls (p<0.001). This was significantly associated with an increase of the inflammatory marker C-reactive protein (CRP) (p<0.01). In the multivariate analysis (adjusted for age, gender, body mass index (BMI), white blood cell (WBC) count, resistin and CRP) sol-CXCL16 was associated with Crohn's disease above versus below the median (OR 10.53 (3.97-27.78) p<0.001) and ulcerative colitis (OR 3.46 (1.40-8.55) p<0.01). Conclusion. Our findings suggest that CXCL16 may play a pro-inflammatory role in IBD, particularly Crohn's disease.
AU  - Lehrke, M.*
AU  - Konrad, A.*
AU  - Schachinger, V.*
AU  - Tillack, C.*
AU  - Seibold, F.*
AU  - Stark, R.G.
AU  - Parhofer, K.G.*
AU  - Broedl, U.C.*
C1  - 2937
C2  - 25241
SP  - 283-288
TI  - CXCL16 is a surrogate marker of inflammatory bowel disease.
JO  - Scand. J. Gastroenterol.
VL  - 43
IS  - 3
PB  - Taylor & Francis
PY  - 2008
SN  - 0036-5521
ER  - 

TY  - JOUR
AB  - The therapeutic effect of Nd-YAG laser coagulation in arterial ulcer bleeding seems to be improved by local epinephrine infiltration. The purpose of this animal study was to evaluate the safety of this new therapeutic modality. The effect of Nd-YAG laser on normal and on infiltrated gastric mucosa was compared in acute and chronic experiments on 14 beagle dogs. On exposed normal gastric wall, perforation time and power output were inversely correlated. The required energies are nearly constant at different power levels. After infiltration of sodium chloride as well as of epinephrine into the mucosa, however, perforation time increased four- to live-fold. Volumes of mucosa defects and of the coagulation zones were also lower after pretreatment by infiltration. The results encourage further clinical use of this new therapeutic approach.
AU  - Heldwein, W.
AU  - Lehnert, P.F.
AU  - Wiebecke, B.
AU  - Ruprecht, L.
AU  - Unsöld, E.
C1  - 42619
C2  - 36449
SP  - 64-69
TI  - Improvement of endoscopic laser therapy in gastrointestinal ulcer bleeding by tissue infiltration basic experiments on the dog stomach in vivo.
JO  - Scand. J. Gastroenterol.
VL  - 22
IS  - 139
PY  - 1987
SN  - 0036-5521
ER  -